ALBUQUERQUE, N.M., March 22 /PRNewswire/ -- Protalex, Inc. (OTC Bulletin Board: PRTX), a biopharmaceutical firm, announced today two significant milestones in its recent history. First, the company, formerly known as Enerdyne Corporation, has returned to trading on the OTC Bulletin Board with a new symbol (PRTX) and a new mission: developing a novel approach to treating Rheumatoid Arthritis. Second, the company announced the successful completion of the cell culture phase of its research plan, and the beginning of animal studies of its unique BioRegulator product. John Doherty, Protalex's President, announced, "The Protalex BioRegulator drug methodology operates on a completely different principle than existing treatment regimens. It works with the host's own natural defense system to arrest the disease process, rather than simply masking the symptoms." The unique Protalex technology is based upon discoveries made by Paul Mann, Ph.D., over decades of research into the immune system. Dr. Mann, a Director of the Company and head of Research and Product Development, has explored the properties of several products that affect the "information management" mechanisms in the body. Cells normally communicate with each other by chemical signals that pass back and forth to keep their functions in balance. In many disease states, it is thought that erroneous signals cause garbled messages that lead to abnormal cell function and tissue damage. Dr. Mann discovered that certain natural and synthetic compounds can restore aspects of the normal balance between tissues, halting the disease process itself. This means that treatment can be discontinued once normal tissue functioning is re-established. Furthermore, if the disease process is one that involves differentiation of cells, some degree of repair of damaged tissues should be expected. These concepts are crucial for the treatment of Rheumatoid Arthritis. Rheumatoid arthritis affects more than 2 million people in the United States alone, most of whom are less than 65 years old. Presently there is no effective cure for this chronic and disabling disorder, and available medications provide variable relief of symptoms but have only minimal effect upon the disease process. The Protalex BioRegulator product promises to be the prototype for an entirely new class of drugs that can arrest or even reverse the course of the disease and thereby restore the quality of life for hundreds of thousands of people suffering from Rheumatoid Arthritis. Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the Company's limited operating history, uncertainty regarding viability and market acceptance of the Company's products, and the Company's dependence on reimbursement by third parties. These factors and others are more fully described in the section entitled "Risks Related to the Company's Business" in the Company's Registration Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and Exchange Commission.
SOURCE Protalex, Inc.